Integra LifeSciences (NASDAQ:IART) Price Target Lowered to $26.00 at Bank of America

Integra LifeSciences (NASDAQ:IART) had its price objective cut by Bank of America from $42.00 to $26.00 in a report published on Tuesday morning, Benzinga reports. They currently have an underperform rating on the life sciences company’s stock.

Several other analysts have also weighed in on the company. JMP Securities lowered their price objective on Integra LifeSciences from $55.00 to $49.00 and set a market outperform rating for the company in a report on Thursday, February 29th. Oppenheimer lowered Integra LifeSciences from an outperform rating to a market perform rating in a report on Tuesday. StockNews.com lowered Integra LifeSciences from a buy rating to a hold rating in a report on Tuesday, April 30th. Truist Financial lowered their price objective on Integra LifeSciences from $46.00 to $41.00 and set a hold rating for the company in a report on Friday, March 1st. Finally, Citigroup raised Integra LifeSciences from a sell rating to a neutral rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has an average rating of Hold and an average price target of $36.80.

Integra LifeSciences Trading Up 8.4 %

NASDAQ:IART opened at $25.08 on Tuesday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a one year low of $22.36 and a one year high of $51.12. The business’s 50-day simple moving average is $32.95 and its 200 day simple moving average is $38.24. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of 30.22, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Monday, May 6th. The life sciences company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $368.90 million for the quarter, compared to analysts’ expectations of $361.96 million. During the same quarter in the previous year, the firm posted $0.74 earnings per share. The company’s revenue was down 3.2% compared to the same quarter last year. As a group, sell-side analysts predict that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC boosted its position in shares of Integra LifeSciences by 54.3% during the first quarter. Headlands Technologies LLC now owns 4,764 shares of the life sciences company’s stock worth $169,000 after buying an additional 1,677 shares during the period. Inspire Investing LLC lifted its position in Integra LifeSciences by 14.8% in the first quarter. Inspire Investing LLC now owns 10,143 shares of the life sciences company’s stock worth $360,000 after purchasing an additional 1,311 shares during the period. Concurrent Investment Advisors LLC lifted its position in Integra LifeSciences by 17.3% in the first quarter. Concurrent Investment Advisors LLC now owns 16,943 shares of the life sciences company’s stock worth $601,000 after purchasing an additional 2,500 shares during the period. Quantbot Technologies LP lifted its position in Integra LifeSciences by 235.1% in the first quarter. Quantbot Technologies LP now owns 43,991 shares of the life sciences company’s stock worth $1,559,000 after purchasing an additional 30,865 shares during the period. Finally, Duality Advisers LP lifted its position in Integra LifeSciences by 103.6% in the first quarter. Duality Advisers LP now owns 59,916 shares of the life sciences company’s stock worth $2,124,000 after purchasing an additional 30,484 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.